Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

A Combination Of Approved Antibodies Overcomes Resistance Of Lung Cancer To Osimertinib By Blocking Bypass Pathways.

Romaniello D, Mazzeo L, Mancini M, Marrocco I, Noronha A, Kreitman MS, Srivastava S, Ghosh S, Lindzen M, Salame TM, Onn A, Bar J, Yarden Y.

Clin Cancer Res. 2018 Jul 2. pii: clincanres.0450.2018. doi: 10.1158/1078-0432.CCR-18-0450. [Epub ahead of print]

PMID:
29967248
2.

SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors.

Roth L, Srivastava S, Lindzen M, Sas-Chen A, Sheffer M, Lauriola M, Enuka Y, Noronha A, Mancini M, Lavi S, Tarcic G, Pines G, Nevo N, Heyman O, Ziv T, Rueda OM, Gnocchi D, Pikarsky E, Admon A, Caldas C, Yarden Y.

Sci Signal. 2018 Jan 30;11(515). pii: eaan0949. doi: 10.1126/scisignal.aan0949.

PMID:
29382783
3.

An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors.

Mancini M, Gal H, Gaborit N, Mazzeo L, Romaniello D, Salame TM, Lindzen M, Mahlknecht G, Enuka Y, Burton DG, Roth L, Noronha A, Marrocco I, Adreka D, Altstadter RE, Bousquet E, Downward J, Maraver A, Krizhanovsky V, Yarden Y.

EMBO Mol Med. 2018 Feb;10(2):294-308. doi: 10.15252/emmm.201708076.

4.

Epigenetic mechanisms underlie the crosstalk between growth factors and a steroid hormone.

Enuka Y, Feldman ME, Chowdhury A, Srivastava S, Lindzen M, Sas-Chen A, Massart R, Cheishvili D, Suderman MJ, Zaltsman Y, Mazza CA, Shukla K, Körner C, Furth N, Lauriola M, Oren M, Wiemann S, Szyf M, Yarden Y.

Nucleic Acids Res. 2017 Dec 15;45(22):12681-12699. doi: 10.1093/nar/gkx865.

5.

Database-independent Protein Sequencing (DiPS) Enables Full-length de Novo Protein and Antibody Sequence Determination.

Savidor A, Barzilay R, Elinger D, Yarden Y, Lindzen M, Gabashvili A, Adiv Tal O, Levin Y.

Mol Cell Proteomics. 2017 Jun;16(6):1151-1161. doi: 10.1074/mcp.O116.065417. Epub 2017 Mar 27.

6.

A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors.

Gelfo V, Rodia MT, Pucci M, Dall'Ora M, Santi S, Solmi R, Roth L, Lindzen M, Bonafè M, Bertotti A, Caramelli E, Lollini PL, Trusolino L, Yarden Y, D'Uva G, Lauriola M.

Oncotarget. 2016 Nov 1;7(44):72167-72183. doi: 10.18632/oncotarget.12354.

7.

Bortezomib-induced pro-inflammatory macrophages as a potential factor limiting anti-tumour efficacy.

Beyar-Katz O, Magidey K, Ben-Tsedek N, Alishekevitz D, Timaner M, Miller V, Lindzen M, Yarden Y, Avivi I, Shaked Y.

J Pathol. 2016 Jul;239(3):262-73. doi: 10.1002/path.4723. Epub 2016 Apr 29.

PMID:
27037906
8.

Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.

Gaborit N, Lindzen M, Yarden Y.

Hum Vaccin Immunother. 2016 Mar 3;12(3):576-92. doi: 10.1080/21645515.2015.1102809. Epub 2015 Nov 3. Review.

9.

Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer.

Mancini M, Gaborit N, Lindzen M, Salame TM, Dall'Ora M, Sevilla-Sharon M, Abdul-Hai A, Downward J, Yarden Y.

Sci Signal. 2015 Jun 2;8(379):ra53. doi: 10.1126/scisignal.aaa0725.

PMID:
26038598
10.

An antibody to amphiregulin, an abundant growth factor in patients' fluids, inhibits ovarian tumors.

Carvalho S, Lindzen M, Lauriola M, Shirazi N, Sinha S, Abdul-Hai A, Levanon K, Korach J, Barshack I, Cohen Y, Onn A, Mills G, Yarden Y.

Oncogene. 2016 Jan 28;35(4):438-47. doi: 10.1038/onc.2015.93. Epub 2015 Apr 27.

PMID:
25915843
11.

Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer.

Ben-Chetrit N, Chetrit D, Russell R, Körner C, Mancini M, Abdul-Hai A, Itkin T, Carvalho S, Cohen-Dvashi H, Koestler WJ, Shukla K, Lindzen M, Kedmi M, Lauriola M, Shulman Z, Barr H, Seger D, Ferraro DA, Pareja F, Gil-Henn H, Lapidot T, Alon R, Milanezi F, Symons M, Ben-Hamo R, Efroni S, Schmitt F, Wiemann S, Caldas C, Ehrlich M, Yarden Y.

Sci Signal. 2015 Jan 20;8(360):ra7. doi: 10.1126/scisignal.2005537.

PMID:
25605973
12.

Examination of HER3 targeting in cancer using monoclonal antibodies.

Gaborit N, Abdul-Hai A, Mancini M, Lindzen M, Lavi S, Leitner O, Mounier L, Chentouf M, Dunoyer S, Ghosh M, Larbouret C, Chardès T, Bazin H, Pèlegrin A, Sela M, Yarden Y.

Proc Natl Acad Sci U S A. 2015 Jan 20;112(3):839-44. doi: 10.1073/pnas.1423645112. Epub 2015 Jan 6.

13.

Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment.

Lauriola M, Enuka Y, Zeisel A, D'Uva G, Roth L, Sharon-Sevilla M, Lindzen M, Sharma K, Nevo N, Feldman M, Carvalho S, Cohen-Dvashi H, Kedmi M, Ben-Chetrit N, Chen A, Solmi R, Wiemann S, Schmitt F, Domany E, Yarden Y.

Nat Commun. 2014 Oct 3;5:5073. doi: 10.1038/ncomms6073.

14.

Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR.

Ferraro DA, Gaborit N, Maron R, Cohen-Dvashi H, Porat Z, Pareja F, Lavi S, Lindzen M, Ben-Chetrit N, Sela M, Yarden Y.

Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1815-20. doi: 10.1073/pnas.1220763110. Epub 2013 Jan 14.

15.

A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis.

Lindzen M, Carvalho S, Starr A, Ben-Chetrit N, Pradeep CR, Köstler WJ, Rabinkov A, Lavi S, Bacus SS, Yarden Y.

Oncogene. 2012 Jul 26;31(30):3505-15. doi: 10.1038/onc.2011.518. Epub 2011 Nov 21.

16.

Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands.

Lindzen M, Lavi S, Leitner O, Yarden Y.

Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12559-63. doi: 10.1073/pnas.1006218107. Epub 2010 Jun 28.

17.

A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration.

Katz M, Amit I, Citri A, Shay T, Carvalho S, Lavi S, Milanezi F, Lyass L, Amariglio N, Jacob-Hirsch J, Ben-Chetrit N, Tarcic G, Lindzen M, Avraham R, Liao YC, Trusk P, Lyass A, Rechavi G, Spector NL, Lo SH, Schmitt F, Bacus SS, Yarden Y.

Nat Cell Biol. 2007 Aug;9(8):961-9. Epub 2007 Jul 22.

PMID:
17643115
18.

Functional interactions of phospholemman (PLM) (FXYD1) with Na+,K+-ATPase. Purification of alpha1/beta1/PLM complexes expressed in Pichia pastoris.

Lifshitz Y, Lindzen M, Garty H, Karlish SJ.

J Biol Chem. 2006 Jun 9;281(23):15790-9. Epub 2006 Apr 11.

19.

Structural interactions between FXYD proteins and Na+,K+-ATPase: alpha/beta/FXYD subunit stoichiometry and cross-linking.

Lindzen M, Gottschalk KE, Füzesi M, Garty H, Karlish SJ.

J Biol Chem. 2006 Mar 3;281(9):5947-55. Epub 2005 Dec 21.

20.

Covalent cross-links between the gamma subunit (FXYD2) and alpha and beta subunits of Na,K-ATPase: modeling the alpha-gamma interaction.

Füzesi M, Gottschalk KE, Lindzen M, Shainskaya A, Küster B, Garty H, Karlish SJ.

J Biol Chem. 2005 May 6;280(18):18291-301. Epub 2005 Mar 2.

21.

Domains involved in the interactions between FXYD and Na,K-ATPase.

Lindzen M, Aizman R, Lifshitz Y, Füzesi M, Karlish SJ, Garty H.

Ann N Y Acad Sci. 2003 Apr;986:530-1. No abstract available.

PMID:
12763878
22.

A specific functional interaction between CHIF and Na,K-ATPase: role of FXYD proteins in the cellular regulation of the pump.

Garty H, Lindzen M, Füzesi M, Aizman R, Goldshleger R, Asher C, Karlish SJ.

Ann N Y Acad Sci. 2003 Apr;986:395-400. Review.

PMID:
12763856
23.

Structure-function relations of interactions between Na,K-ATPase, the gamma subunit, and corticosteroid hormone-induced factor.

Lindzen M, Aizman R, Lifshitz Y, Lubarski I, Karlish SJ, Garty H.

J Biol Chem. 2003 May 23;278(21):18738-43. Epub 2003 Mar 7.

24.

A functional interaction between CHIF and Na-K-ATPase: implication for regulation by FXYD proteins.

Garty H, Lindzen M, Scanzano R, Aizman R, Füzesi M, Goldshleger R, Farman N, Blostein R, Karlish SJ.

Am J Physiol Renal Physiol. 2002 Oct;283(4):F607-15.

Supplemental Content

Loading ...
Support Center